The FDA is rolling out an aggressive plan to make generative AI a linchpin in its decision-making, part of a bid to get faster and leaner in evaluating drugs, foods, medical devices and diagnostic ...

Intellia Therapeutics reported further progress with two treatments that are now ensconced in Phase III of testing. Click ...

Meanwhile, Axios reports the FDA is making plans to use AI in its decision-making. Also: President Donald Trump is set to sign an executive order to bring down the cost of meds.

Avant Technologies, Inc. (OTCQB: AVAI) ("Avant" or the "Company"), and its JV partner, Ainnova Tech, Inc., (Ainnova), a leading healthcare technology company focused on revolutionizing early disease ...

The FDA has started exploring how AI can be used to accelerate drug approvals in collaboration with OpenAI amid oversight ...

OpenAI has reportedly met with officials from the U.S. Food and Drug Administration (FDA) to discuss the use of artificial ...

The U.S. Food and Drug Administration (FDA) has unveiled a historic initiative to implement artificial intelligence (AI) ...

For Charles Awoniyi, he stands at the forefront of healthcare transformation, leveraging his expertise in artificial ...

Supposedly, the AI tool will speed up the FDA's drug review process by reducing the time its scientists have to spend doing ...

In a historic first for the agency, FDA Commissioner Martin A. Makary, M.D., M.P.H. announced an aggressive timeline to scale use of artificial intelligence ...

Their pitch to consumers is straightforward: Upload your receipts and receive points towards gift cards in exchange. All of ...

FDA will implement a secure generative AI system across all centers by June 30, aiming to streamline internal reviews and ...